Frontiers in systems biology最新文献

筛选
英文 中文
A Pseudomonas fluorescens AND-gate biosensor for protein expression at plant root proximity. 荧光假单胞菌与门生物传感器在植物根系附近的蛋白表达。
IF 2.3
Frontiers in systems biology Pub Date : 2025-07-30 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1620608
Nico van Donk, Antoine Raynal, Enrique Asin-Garcia
{"title":"A <i>Pseudomonas fluorescens</i> AND-gate biosensor for protein expression at plant root proximity.","authors":"Nico van Donk, Antoine Raynal, Enrique Asin-Garcia","doi":"10.3389/fsysb.2025.1620608","DOIUrl":"10.3389/fsysb.2025.1620608","url":null,"abstract":"<p><p>By 2050, global population growth will significantly increase food demand, placing additional pressure on agriculture, a sector already vulnerable to climate change. Traditional approaches like fertilizers and pesticides have helped boost yields but are increasingly seen as unsustainable. As bioengineering becomes more accessible, engineered soil microorganisms are emerging as promising alternatives. However, their application in the rhizosphere is often limited by poor survivability and the high metabolic cost of expressing heterologous genes without appropriate regulation. To address this, we developed a microbial whole-cell biosensor that activates gene expression only under favorable conditions: in close proximity to plant roots and at high bacterial population densities. We engineered the pSal/nahR system in our host <i>Pseudomonas fluorescens</i> SBW25 to respond to salicylic acid, a key root exudate. In parallel, we implemented a quorum sensing system based on LuxI and the luxpR/LuxR pair to monitor cell density. Both inputs were integrated using a toehold switch-based AND gate, triggering expression only when both conditions were met. This strategy minimizes metabolic burden and offers a tightly controlled system for expression at target locations. While further validation in rhizosphere-like conditions is required, our results provide a foundation for safer open-environment applications of microorganisms, making this biosensor a versatile tool for future agricultural biotechnology.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1620608"},"PeriodicalIF":2.3,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammation mediated brain damage and cytokine expression in a maternally derived murine model for preterm hypoxic-ischemic encephalopathy. 炎症介导的脑损伤和细胞因子表达的母源小鼠模型早产缺氧缺血性脑病。
IF 2.3
Frontiers in systems biology Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1517712
Tyler C Hillman, Braeden Jacobson, Kiara Piaggio Hurtado De Medoza, Marlene Lopez, Nicholas Iwakoshi, Christopher G Wilson
{"title":"Inflammation mediated brain damage and cytokine expression in a maternally derived murine model for preterm hypoxic-ischemic encephalopathy.","authors":"Tyler C Hillman, Braeden Jacobson, Kiara Piaggio Hurtado De Medoza, Marlene Lopez, Nicholas Iwakoshi, Christopher G Wilson","doi":"10.3389/fsysb.2025.1517712","DOIUrl":"10.3389/fsysb.2025.1517712","url":null,"abstract":"<p><strong>Introduction: </strong>Preterm hypoxic-ischemic encephalopathy (pHIE) is a complex brain injury that contributes to chronic neural inflammation and neurological disorders. The signs and symptoms of in utero pHIE can often be overlooked, untreated or lumped into more generic conditions such as encephalopathy of prematurity (EOP). Clinical interventions like hypothermia and erythropoietin do not improve pHIE. We characterized a murine model for pHIE, which includes hypoxia and maternal factors as a cost-effective alternative to large animal models of HIE.</p><p><strong>Methods: </strong>We injected pregnant mouse dams with LPS to stimulate an inflammatory response on embryonic days 15-16 (E15-E16), and whole cage hypoxia exposures occurred from postnatal days 3 to 9. To quantify the development of inflammation in the pHIE model, we used immunohistochemistry to stain for Caspase-9 in the cortex (20 μm per slice) and then counted Caspase-9 positive cells using unbiased stereology. We stained brain tissue with MAP2 to quantify neuronal intermediate filament expression and staining using a machine-learning based image analysis approach. We quantified cytokines (IL-1β, IL-6, IL-10, IL-18 and TNF-α) using RT-qPCR and (IL-18) ELISA to characterize differential expression in all treatment groups. The pHIE animals were compared with controls (LPS-Normoxia, Saline-Hypoxia, Saline-Normoxia, and Naïve) and with a model of only hypoxia (10% O<sub>2</sub>) exposure in mouse pups.</p><p><strong>Results: </strong>The pHIE pups showed significantly higher expression of Caspase-9 throughout the cortex compared to Naïve pup brains (p < 0.05). MAP2 expression was significantly decreased (p < 0.05) between 1.5-6.0 mm of the brain compared to Saline-Hypoxia and Naïve animals. Both IL-1β and IL-10 expression in LPS-Hypoxia animals was significantly higher (p < 0.05) than in Saline-Hypoxia and Naive animals. TNF-α expression was not significantly different between LPS-Hypoxia and Saline-Hypoxia animals. However, both showed significantly different transcription, compared to Naive animals.</p><p><strong>Discussion: </strong>The model we describe here shows cortical damage similar to that seen in human HIE.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1517712"},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enzyme-displaying spores as a novel strategy for mixed fiber textile recycling. 显示酶的孢子作为混合纤维纺织品回收的新策略。
IF 2.6
Frontiers in systems biology Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1603731
Matti Lehmann, Max Herrmann
{"title":"Enzyme-displaying spores as a novel strategy for mixed fiber textile recycling.","authors":"Matti Lehmann, Max Herrmann","doi":"10.3389/fsysb.2025.1603731","DOIUrl":"10.3389/fsysb.2025.1603731","url":null,"abstract":"<p><p>Global textile manufacturing practices are responsible for an increasing amount of textile waste that pollutes our planet. Mixed fiber blends pose a recycling challenge due to their heterogeneous structure. Current mechanical, chemical, thermochemical and enzymatic strategies suffer from several limitations such as high energy costs, extensive pre-treatment requirements and enzyme instability. This mini-review aims to present recent developments in the research field and to introduce Spore Surface Display (SSD) technology as a new biological approach for mixed textile degradation. SSD allows enzymes to be anchored on the robust bacterial spore surface, immobilizing multiple enzymes required for simultaneous cotton-polyester degradation into their respective monomers. The mini-review also includes an initial proposal for a process design suitable for a full mixed textile degradation process using this synthetic biology approach.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1603731"},"PeriodicalIF":2.6,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors. 探索这种脱节:SGLT2抑制剂缺乏身体功能改善的机制。
IF 2.3
Frontiers in systems biology Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1593229
Cian Sutcliffe, Jack A Sargeant, Thomas Yates, Melanie J Davies, Luke A Baker
{"title":"Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors.","authors":"Cian Sutcliffe, Jack A Sargeant, Thomas Yates, Melanie J Davies, Luke A Baker","doi":"10.3389/fsysb.2025.1593229","DOIUrl":"10.3389/fsysb.2025.1593229","url":null,"abstract":"<p><p>Current evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) do not consistently improve patient physical function, despite improvements in clinical symptoms and reductions in both adiposity and body weight. We highlight heterogenous methodologies in SGLT2i physical function trials. We then provide context to these findings by collating new data which describes how reduced glycaemia with SGLT2i alters numerous physiological processes and discuss how these alterations may diminish or prevent expected functional improvements. Alterations include changes to energy homeostasis, pancreatic hormones, muscle metabolism, physical activity, and appetite regulation. Current evidence in humans is limited and the mechanistic interaction between SGLT2i, skeletal muscle, and physical function remains incompletely understood. Future investigations must embed comprehensive molecular techniques within suitably designed clinical trials to determine how skeletal muscle health and patient mobility is influenced by acute and long term SGLT2i prescription.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1593229"},"PeriodicalIF":2.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants. 氯沙坦与CYP2C9等位基因变异相关的药代动力学和药效学数学模型。
IF 2.3
Frontiers in systems biology Pub Date : 2025-05-21 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1504077
Dmitry Babaev, Elena Kutumova, Fedor Kolpakov
{"title":"Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to <i>CYP2C9</i> allele variants.","authors":"Dmitry Babaev, Elena Kutumova, Fedor Kolpakov","doi":"10.3389/fsysb.2025.1504077","DOIUrl":"10.3389/fsysb.2025.1504077","url":null,"abstract":"<p><p>Losartan is a selective angiotensin II AT1-receptor antagonist for the treatment of arterial hypertension and heart failure. It is converted to a pharmacologically active metabolite carboxylosartan (E-3174) in the liver mainly by CYP2C9 enzyme, a member of the cytochrome P450 superfamily. The gene encoding this protein is highly polymorphic: numerous single nucleotide polymorphisms that alter the enzyme function have been described in the literature. The most widespread <i>CYP2C9</i> alleles are <i>CYP2C9*1</i> (wild-type), <i>CYP2C9*2</i>, and <i>CYP2C9*3</i>. Here we performed mathematical modeling of the metabolism of orally administered losartan to E-3174 taking into account combinations of the most common <i>CYP2C9</i> alleles. Next, using the previously created model of the human cardiovascular and renal systems, we demonstrated that the blood pressure response to losartan therapy in a cohort of virtual hypertensive patients depended on <i>CYP2C9</i> allelic variants. Individuals with the <i>CYP2C9*1/CYP2C9*1</i> genotype responded better to treatment than patients carrying <i>CYP2C9*2</i> or <i>CYP2C9*3</i> alleles. The results of the modeling can potentially be used for personalization of drug therapy for arterial hypertension.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1504077"},"PeriodicalIF":2.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biotechnology systems engineering: preparing the next generation of bioengineers. 生物技术系统工程:培养下一代生物工程师。
IF 2.6
Frontiers in systems biology Pub Date : 2025-04-29 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1583534
Sebastián Espinel-Ríos
{"title":"Biotechnology systems engineering: preparing the next generation of bioengineers.","authors":"Sebastián Espinel-Ríos","doi":"10.3389/fsysb.2025.1583534","DOIUrl":"10.3389/fsysb.2025.1583534","url":null,"abstract":"","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1583534"},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of probiotics, prebiotics, and synbiotics in the treatment of inflammatory bowel diseases: an overview of recent clinical trials. 益生菌、益生元和合成菌在治疗炎症性肠病中的作用:近期临床试验综述
IF 2.6
Frontiers in systems biology Pub Date : 2025-04-16 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1561047
Fayez Yassine, Adam Najm, Melhem Bilen
{"title":"The role of probiotics, prebiotics, and synbiotics in the treatment of inflammatory bowel diseases: an overview of recent clinical trials.","authors":"Fayez Yassine, Adam Najm, Melhem Bilen","doi":"10.3389/fsysb.2025.1561047","DOIUrl":"10.3389/fsysb.2025.1561047","url":null,"abstract":"<p><strong>Background: </strong>The increasing incidence of inflammatory bowel diseases (IBD) over the last two decades has prompted the need to create new types of therapeutic interventions. The gut microbiome has emerged as a key component in the prognosis and pathophysiology of IBDs. The alteration or dysbiosis of the gut microbiome has been shown to exacerbate IBDs. The bacterial composition of the gut microbiome can be modulated through the usage of probiotics, prebiotics, and synbiotics. These interventions induce the growth of beneficial bacteria. Additionally, these interventions could be used to maintain gut homeostasis, reduce the inflammation seen in these morbidities, and strengthen the gut epithelial barrier.</p><p><strong>Methods: </strong>The literature review was conducted in October 2024 using PubMed, Scopus, and Google Scholar screening for recent clinical trials in addition to reviews relevant to the topic.</p><p><strong>Aims: </strong>This review aims to summarize the recent clinical trials of probiotics, prebiotics, and synbiotics in IBD patients highlighting their potential benefits in alleviating symptoms and enhancing the quality of life.</p><p><strong>Conclusion: </strong>Certain probiotic formulations such as single strain ones consisting of <i>Lactobacillus,</i> or mixed-strain combinations of <i>Lactobacillus</i> and <i>Bifidobacterium</i>, prebiotic compounds such as fructooligosaccharides, and synbiotic combinations of both have proven effective in improving the clinical, immunological, and symptomatic aspects of the disease course. While promising, these findings remain inconclusive due to inconsistent study designs, small sample sizes, and varying patient responses. This emphasizes the need for larger, well-controlled trials to determine their clinical efficacy.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1561047"},"PeriodicalIF":2.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scientia machina: a proposed conceptual framework for a technology-accelerated system of biomedical science. 机械科学:生物医学科学技术加速系统的拟议概念框架。
IF 2.6
Frontiers in systems biology Pub Date : 2025-03-13 eCollection Date: 2025-01-01 DOI: 10.3389/fsysb.2025.1576989
Sean T Manion
{"title":"Scientia machina: a proposed conceptual framework for a technology-accelerated system of biomedical science.","authors":"Sean T Manion","doi":"10.3389/fsysb.2025.1576989","DOIUrl":"10.3389/fsysb.2025.1576989","url":null,"abstract":"","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"5 ","pages":"1576989"},"PeriodicalIF":2.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multi-omics strategy to understand PASC through the RECOVER cohorts: a paradigm for a systems biology approach to the study of chronic conditions. 通过RECOVER队列了解PASC的多组学策略:慢性病研究系统生物学方法的范例。
IF 2.6
Frontiers in systems biology Pub Date : 2025-01-07 eCollection Date: 2024-01-01 DOI: 10.3389/fsysb.2024.1422384
Jun Sun, Masanori Aikawa, Hassan Ashktorab, Noam D Beckmann, Michael L Enger, Joaquin M Espinosa, Xiaowu Gai, Benjamin D Horne, Paul Keim, Jessica Lasky-Su, Rebecca Letts, Cheryl L Maier, Meisha Mandal, Lauren Nichols, Nadia R Roan, Mark W Russell, Jacqueline Rutter, George R Saade, Kumar Sharma, Stephanie Shiau, Stephen N Thibodeau, Samuel Yang, Lucio Miele
{"title":"A multi-omics strategy to understand PASC through the RECOVER cohorts: a paradigm for a systems biology approach to the study of chronic conditions.","authors":"Jun Sun, Masanori Aikawa, Hassan Ashktorab, Noam D Beckmann, Michael L Enger, Joaquin M Espinosa, Xiaowu Gai, Benjamin D Horne, Paul Keim, Jessica Lasky-Su, Rebecca Letts, Cheryl L Maier, Meisha Mandal, Lauren Nichols, Nadia R Roan, Mark W Russell, Jacqueline Rutter, George R Saade, Kumar Sharma, Stephanie Shiau, Stephen N Thibodeau, Samuel Yang, Lucio Miele","doi":"10.3389/fsysb.2024.1422384","DOIUrl":"10.3389/fsysb.2024.1422384","url":null,"abstract":"<p><p>Post-Acute Sequelae of SARS-CoV-2 infection (PASC or \"Long COVID\"), includes numerous chronic conditions associated with widespread morbidity and rising healthcare costs. PASC has highly variable clinical presentations, and likely includes multiple molecular subtypes, but it remains poorly understood from a molecular and mechanistic standpoint. This hampers the development of rationally targeted therapeutic strategies. The NIH-sponsored \"Researching COVID to Enhance Recovery\" (RECOVER) initiative includes several retrospective/prospective observational cohort studies enrolling adult, pregnant adult and pediatric patients respectively. RECOVER formed an \"OMICS\" multidisciplinary task force, including clinicians, pathologists, laboratory scientists and data scientists, charged with developing recommendations to apply cutting-edge system biology technologies to achieve the goals of RECOVER. The task force met biweekly over 14 months, to evaluate published evidence, examine the possible contribution of each \"omics\" technique to the study of PASC and develop study design recommendations. The OMICS task force recommended an integrated, longitudinal, simultaneous systems biology study of participant biospecimens on the entire RECOVER cohorts through centralized laboratories, as opposed to multiple smaller studies using one or few analytical techniques. The resulting multi-dimensional molecular dataset should be correlated with the deep clinical phenotyping performed through RECOVER, as well as with information on demographics, comorbidities, social determinants of health, the exposome and lifestyle factors that may contribute to the clinical presentations of PASC. This approach will minimize lab-to-lab technical variability, maximize sample size for class discovery, and enable the incorporation of as many relevant variables as possible into statistical models. Many of our recommendations have already been considered by the NIH through the peer-review process, resulting in the creation of a systems biology panel that is currently designing the studies we proposed. This system biology strategy, coupled with modern data science approaches, will dramatically improve our prospects for accurate disease subtype identification, biomarker discovery and therapeutic target identification for precision treatment. The resulting dataset should be made available to the scientific community for secondary analyses. Analogous system biology approaches should be built into the study designs of large observational studies whenever possible.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"4 ","pages":"1422384"},"PeriodicalIF":2.6,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement in the prediction power of an astrocyte genome-scale metabolic model using multi-omic data. 利用多组学数据提高星形细胞基因组尺度代谢模型的预测能力。
IF 2.3
Frontiers in systems biology Pub Date : 2025-01-03 eCollection Date: 2024-01-01 DOI: 10.3389/fsysb.2024.1500710
Andrea Angarita-Rodríguez, Nicolás Mendoza-Mejía, Janneth González, Jason Papin, Andrés Felipe Aristizábal, Andrés Pinzón
{"title":"Improvement in the prediction power of an astrocyte genome-scale metabolic model using multi-omic data.","authors":"Andrea Angarita-Rodríguez, Nicolás Mendoza-Mejía, Janneth González, Jason Papin, Andrés Felipe Aristizábal, Andrés Pinzón","doi":"10.3389/fsysb.2024.1500710","DOIUrl":"10.3389/fsysb.2024.1500710","url":null,"abstract":"<p><strong>Introduction: </strong>The availability of large-scale multi-omic data has revolution-ized the study of cellular machinery, enabling a systematic understanding of biological processes. However, the integration of these datasets into Genome-Scale Models of Metabolism (GEMs) re-mains underexplored. Existing methods often link transcriptome and proteome data independently to reaction boundaries, providing models with estimated maximum reaction rates based on individual datasets. This independent approach, however, introduces uncertainties and inaccuracies.</p><p><strong>Methods: </strong>To address these challenges, we applied a principal component analysis (PCA)-based approach to integrate transcriptome and proteome data. This method facilitates the reconstruction of context-specific models grounded in multi-omics data, enhancing their biological relevance and predictive capacity.</p><p><strong>Results: </strong>Using this approach, we successfully reconstructed an astrocyte GEM with improved prediction capabilities compared to state-of-the-art models available in the literature.</p><p><strong>Discussion: </strong>These advancements underscore the potential of multi-omic inte-gration to refine metabolic modeling and its critical role in studying neurodegeneration and developing effective therapies.</p>","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":"4 ","pages":"1500710"},"PeriodicalIF":2.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书